Twitter | Search | |
Sandra Turner
radiation oncologist | med education enthusiast | founding lead campaign | goal: everyone who’d benefit from gets it
8,811
Tweets
4,001
Following
4,222
Followers
Tweets
Sandra Turner retweeted
Matthias Nau Feb 19
Gotta love ! Look at how much the optic nerves move!!! ❤️. Source:
Reply Retweet Like
Sandra Turner retweeted
Mudit Chowdhary Feb 20
⚡️☢️ Phenomenal results in Phase 1/2 TRASTS study in metastatic ! 72% overall response rate with Trabectedin + (30 Gy/10 fxn) In contrast, trabectedin alone shows ORR of only ~10% Link: cc
Reply Retweet Like
Sandra Turner retweeted
Julie McCrossin AM Feb 21
Please share this Forum Flyer with Head & Neck Cancer MDTs Members (Multidisciplinary Teams) in Australia & New Zealand. Thank you!
Reply Retweet Like
Sandra Turner retweeted
Julie McCrossin AM Feb 20
Head & Neck Cancer recovery involves a team. Join multidisciplinary clinicians & patients at 2020 Head & Neck Cancer Forum Sydney Friday 12 June. Registration $25. Patients & family free. ⁩ ⁦⁩ ⁦
Reply Retweet Like
Sandra Turner Feb 18
Reply Retweet Like
Sandra Turner Feb 15
Thanks Sounds like a retrograde move to me without knowing all the details
Reply Retweet Like
Sandra Turner Feb 15
Interested to understand what Step 1 means?
Reply Retweet Like
Sandra Turner retweeted
Shankar Siva Feb 13
David Dearnley from updates CHHiP hypofractionated study in - with 8 yr F/U outcomes are consistent, 60/20 is most promising, with no increase in toxicity with longer term reporting (<2% GU/GI toxicity RTOG 2+)
Reply Retweet Like
Sandra Turner retweeted
Eunji Hwang Feb 15
Day 1 of The Christie Course, starting with an overview by clinical director . The fellows are ready!
Reply Retweet Like
Sandra Turner Feb 14
Correction: 50% cancer patients SHOULD receive In most countries around the world many patients who’d benefit miss out. Hence education/awareness campaigns eg Agree- med student curricula vital focus
Reply Retweet Like
Sandra Turner retweeted
Julie McCrossin AM Feb 13
Reply Retweet Like
Sandra Turner retweeted
Mudit Chowdhary Feb 9
Hepatocellular carcinoma is a leading cause of cancer mortality <30% pts eligible for curative Sx or transplant SBRT is a promising tx option for these pts, in addition to ablation, TACE, TARE Here are 3 recent exciting studies of SBRT in HCC 1/5
Reply Retweet Like
Sandra Turner Feb 11
Inspiring yet sad story- failure to refer to till too late. Why we need to raise awareness of this critical cancer tmt Would I have escaped paralysis if I’d had radiotherapy?
Reply Retweet Like
Sandra Turner retweeted
Medicine Matters oncology Feb 6
The 2020 Genitourinary Cancers Symposium (ASCO GU 2020), hosted by ASCO and co-sponsored by ASTRO and SUO, takes place February 13–15 2020 in San Francisco, USA. We will be providing news articles and video interviews with experts around the latest data presented at the meeting.
Reply Retweet Like
Sandra Turner retweeted
Nicholas Zaorsky, MD MS Feb 7
is all over again: Surgeons acquiring ownership of devices increases self-referral and use
Reply Retweet Like
Sandra Turner Feb 10
Helpful diagram for those of us who do sarcoma
Reply Retweet Like
Sandra Turner Feb 10
Something wonky happened to our group photo so here is it again!
Reply Retweet Like
Sandra Turner retweeted
Oncology Advance Feb 7
Submit your paper on and Geriatric oncology in journal for Special issue edited by and Richard Simcock
Reply Retweet Like
Sandra Turner retweeted
Richard Simcock Jan 26
You can read the Journal Club from last week here: And you can even share it with those foolish enough not to be on Twitter...
Reply Retweet Like
Sandra Turner retweeted
Dr. Andrew Loblaw Feb 8
use in tripled in use in US between 2010-2015 for favourable risk patients (LR, FIR), doubled in UIR but remained stable for HR pts. See it in , link below I wonder what it is in 2019 now that -RT-PC out?
Reply Retweet Like